Pentosan Polysulfate Sodium
**Pentosan Polysulfate Sodium (PPS)** is a semi-synthetic, heparin-like macromolecular carbohydrate derivative derived from Beechwood hemicellulose. It is primarily utilized in veterinary medicine as a **Disease-Modifying Osteoarthritis Drug (DMOAD)** and as an adjunctive therapy for lower urinary tract conditions. Key clinical applications include: * **Osteoarthritis (OA):** Used in dogs, cats, and horses to improve joint function, reduce inflammation, and promote cartilage health. * **Feline Idiopathic Lower Urinary Tract Disease (FLUTD) / Interstitial Cystitis:** Used off-label to help restore the protective glycosaminoglycan (GAG) layer of the bladder urothelium, though clinical efficacy for short-term acute flare-ups is not well-documented. *Clinical Pearl:* While structurally related to heparin, its anticoagulant activity is significantly weaker (approximately 1/15th that of heparin). However, caution is still warranted in patients with bleeding disorders or those undergoing surgery.
Mecanismo: Pentosan polysulfate sodium exhibits multiple pharmacological effects depending on the target tissue: * **Osteoarthritis (Disease-Modifying Effects):** * **Inhibits catabolic enzymes:** Downregulates **matrix metalloproteinases (MMPs)** and **aggrecanases** that degrade articular cartilage. * **Stimulates matrix synthesis:** Promotes the synthesis of **hyaluronic acid** by synovial fibroblasts and preserves proteoglycan content within the cartilage matrix. * **Improves microcirculation:** Its mild anticoagulant, fibrinolytic, and hypolipidemic properties help mobilize thrombi and lipid deposits in subchondral blood vessels, thereby increasing synovial blood flow and nutrition to the joint. * **Interstitial Cystitis / FLUTD:** * **Urothelial Protection:** Excreted partially unchanged in the urine, PPS adheres to the mucosal membranes of the bladder wall. It acts as a synthetic **glycosaminoglycan (GAG) buffer**, preventing irritating urinary solutes and toxins from reaching and damaging the underlying transitional epithelial cells. * **Analgesia:** Provides mild local analgesic and anti-inflammatory effects within the bladder wall.
Dosificación por especie
- Persistent or recurrent FLUTD · 2-16 mg/kg PO q12h · PO · q12h · Recent studies have not shown any statistical benefit.
- Persistent or recurrent FLUTD · 8 mg/kg PO q12h · PO · q12h · Recent studies have not shown any statistical benefit.
- Osteoarthritis · 3 mg/kg IM on four occasions with an interval of 7 days between injections. · IM · q7d · 4 doses
- Osteoarthritis · Inject mixture back into joint · Intra-articular · Once · Prepare site as for surgery. Avoid iodine based skin preps; use neutral soapless cleanser. Withdraw ~1 mL synovial fluid, mix with pentosan in syringe, inject back. Firmly bandage and confine for 3-4 hours. Rest horse for 2 weeks, follow with 2 weeks graded walking.
- Osteoarthritis (High loading dose for treatment of OA signs of pain, lameness and stiffness) · 20 mg/kg PO twice weekly for 5 weeks · PO · twice weekly · 5 weeks · Always give on an empty stomach.
- Osteoarthritis (Medium Loading dose for management of OA after joint surgery) · 10 mg/kg PO once weekly for 12 weeks · PO · once weekly · 12 weeks · Always give on an empty stomach.
- Osteoarthritis (Maintenance dose) · 10 mg/kg once weekly for 4 weeks as needed · PO · once weekly · 4 weeks · Always give on an empty stomach.
- Osteoarthritis · 3 mg/kg IM or SC on four occasions with an interval of 5-7 days between injections · IM/SC · q5-7d · 4 doses
Vías de administración
Contraindicaciones
- Known hypersensitivity to pentosan polysulfate sodium
- Patients with active bleeding disorders
- Use with caution prior to surgery
Efectos adversos
- Vomiting
- Anorexia
- Lethargy
- Mild depression
- Bleeding or prolonged coagulation times (dose-dependent increase in PTT in horses)
- Transient increases in liver enzymes (reported in humans)
Interacciones farmacológicas
- NSAIDs (e.g., carprofen, meloxicam) · May increase the risk of bleeding due to concurrent effects on coagulation and platelet function; use cautiously.
- Aspirin · Increased risk of bleeding due to combined anticoagulant and antiplatelet effects.
- Heparin · Additive anticoagulant effects; increased risk of hemorrhage.
Monitorización
- Clinical efficacy (improvement in lameness/mobility for OA, or reduction in urinary signs for FLUTD)
- Signs of bleeding or bruising
- Intra-articular bleeding (when administered directly into joints)
Sobredosis
Information regarding overdoses is limited. * **Potential Signs:** Overdoses could potentially cause bleeding, thrombocytopenia, gastrointestinal distress, and liver function abnormalities. * **Treatment:** Treatment recommendations are basically supportive in nature. If an acute oral overdose occurs, consider standard protocols for drug removal from the gut (e.g., emesis, activated charcoal) if performed promptly.
La referencia de fármacos de VetSheet está destinada a veterinarios colegiados como apoyo a la decisión clínica, no sustituye el juicio profesional ni la ficha técnica vigente del fabricante.